Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 4th ESH Erythro Meeting took place in Dublin, Ireland, and virtually from March 14-16, 2025. This meeting brought together experts to discuss the latest in the pathophysiology and treatment of sickle cell disease (SCD) and thalassemia. VJHemOnc covered this meeting virtually.

ESH Erythro 2025

4th Translational Research Conference: Pathophysiology and Clinical Advances in Sickle Cell Disease and Thalassemia
14–16 March 2025 | Dublin, Ireland

ESH Erythro 2025

4th Translational Research Conference: Pathophysiology and Clinical Advances in Sickle Cell Disease and Thalassemia
14–16 March 2025 | Dublin, Ireland
The 4th ESH Erythro Meeting took place in Dublin, Ireland, and virtually from March 14-16, 2025. This meeting brought together experts to discuss the latest in the pathophysiology and treatment of sickle cell disease (SCD) and thalassemia. VJHemOnc covered this meeting virtually.
The growing role of gene editing and gene therapy in SCD & important practical considerations 1:28
The growing role of gene editing and gene therapy in SCD & important practical considerations
Sara El Hoss • 21 Mar 2025
Repurposing drugs in sickle cell disease: lessons learned from hydroxyurea 1:28
Repurposing drugs in sickle cell disease: lessons learned from hydroxyurea
Sara El Hoss • 21 Mar 2025
The impact of ineffective erythropoiesis in hemoglobinopathies & underlying mechanisms 2:21
The impact of ineffective erythropoiesis in hemoglobinopathies & underlying mechanisms
Sara El Hoss • 21 Mar 2025
Potential therapeutic avenues being explored to target inflammation in thalassemia & SCD 2:03
Potential therapeutic avenues being explored to target inflammation in thalassemia & SCD
Francesca Vinchi • 21 Mar 2025
The pathophysiology of inflammation in beta thalassemia and SCD 2:23
The pathophysiology of inflammation in beta thalassemia and SCD
Francesca Vinchi • 21 Mar 2025
The potential benefit of combining luspatercept with iron restriction compounds in MDS & thalassemia 3:09
The potential benefit of combining luspatercept with iron restriction compounds in MDS & thalassemia
Francesca Vinchi • 21 Mar 2025
The impact of luspatercept on fatigue-related QoL in patients with NTD beta thalassemia 2:06
The impact of luspatercept on fatigue-related QoL in patients with NTD beta thalassemia
Maria Domenica Cappellini • 14 Mar 2025
Ongoing research in the field of thalassemia: addressing inflammation & improving erythropoiesis 2:12
Ongoing research in the field of thalassemia: addressing inflammation & improving erythropoiesis
Francesca Vinchi • 21 Mar 2025
Targeting heme-regulated inhibitor kinase in MDS-RS and sickle cell disease 3:47
Targeting heme-regulated inhibitor kinase in MDS-RS and sickle cell disease
Vera Adema • 14 Mar 2025
Promising therapies for SCD & thalassemia: gene therapy, luspatercept, mitapivat & more 5:01
Promising therapies for SCD & thalassemia: gene therapy, luspatercept, mitapivat & more
Perla Eleftheriou • 14 Mar 2025
Key challenges that exist when treating adults with thalassemia & important factors to consider 6:10
Key challenges that exist when treating adults with thalassemia & important factors to consider
Perla Eleftheriou • 14 Mar 2025
Mitapivat: mechanism of action and updates with this agent in thalassemia treatment 3:02
Mitapivat: mechanism of action and updates with this agent in thalassemia treatment
Maria Domenica Cappellini • 18 Mar 2025
Advances in the treatment of SCD & thalassemia: luspatercept, mitapivat, gene therapy, and more 5:14
Advances in the treatment of SCD & thalassemia: luspatercept, mitapivat, gene therapy, and more
Maria Domenica Cappellini • 18 Mar 2025
An overview of gene therapy approaches in SCD & thalassemia: gene addition versus genome editing 4:36
An overview of gene therapy approaches in SCD & thalassemia: gene addition versus genome editing
Maria Domenica Cappellini • 18 Mar 2025
Adult versus pediatric thalassemia: differences in biology and treatment approaches 2:02
Adult versus pediatric thalassemia: differences in biology and treatment approaches
Perla Eleftheriou • 14 Mar 2025
Managing adult patients with thalassemia: the value of a multidisciplinary approach 4:37
Managing adult patients with thalassemia: the value of a multidisciplinary approach
Perla Eleftheriou • 14 Mar 2025
The content of VJHemOnc is intended for healthcare professionals